Promising data on several new breast cancer agents, including one new cytotoxic, were presented at the American Society of Clinical Oncology Breast Cancer Symposium 2011 held September 8-10 in San Francisco, California.
The addition of the novel histone deacetylase (HDAC) inhibitor entinostat to exemestane significantly delayed recurrences and showed a trend for a survival benefit in the phase 2 ENCORE 301 (ENtinostat Combinations Overcoming REsistance) study reported by Denise Yardley, MD, of Sarah Cannon Research Institute and Tennessee Oncology in Nashville.
CHICAGO—In the National Cancer Institute of Canada Clinical Trials Group MA.20 trial, regional nodal irradiation (RNI) added to whole breast irradiation (WBI) improved disease- free survival (DFS), with a trend toward improved overall survival (OS), reported Timothy Whelan, MD, of McMaster University and the Juravinski Cancer Centre in Hamilton, Ontario.
SAN ANTONIO—A rapidly growing, nationwide clinical trial matching service that is user-friendly for patients is enabling more patients to learn about and enroll in clinical trials, said Ellie Cohen, PhD, the program’s director. Cohen described the success of her program at the 33rd annual San Antonio Breast Cancer Symposium.
Results 111 - 120 of 161